Lifeway Foods Inc.
), which manufactures dairy and non-dairy health food products,
posted earnings of 9 cents per share in the third quarter of
2012. The result fell short of the Zacks Consensus Estimate by a
penny, but comfortably beats the year-ago quarter earnings of 6
cents per share.
Gross sales in the quarter rose 16.0% year over year to $22.5
million, driven by higher sales and increased customer acceptance
for its flagship product 'Kefir' as well as other product lines
including Bio Kefir and ProBugs organic Kefir for kids. Net sales
also jumped 16.0% to $20.6 million.
During the quarter, gross profit enhanced 18% to $7.5 million and
gross margin was flat at 33%, attributed to a 20% dip in
conventional costs, the largest ingredient for the company,
partially offset by a 10% hike in the price of milk.
Operating expense nudged up 13% year over year to $5.4 million,
primarily due to higher general and administrative expenses
particularly related to increased investments in marketing and
advertising for brand awareness as well as increased selling and
amortization expenses. However, operating income surged 31.3% to
$2.1 million, aided by an increase in gross margin.
As of September 30, 2012, Lifeway Foods had cash and cash
equivalents of $2.4 million versus $0.86 million at September 30,
2011. Shareholders' equity were $38.4 million versus $35.8
million in the year ago quarter.
Lifeway continues to focus on distributing its flagship product
"Kefir" along with the growth of business. Further, the company
is also making efforts to keep enhancing shareholder's value.
However, the price of milk is likely to be a headwind through the
rest of 2012.
We currently retain a Zacks #3 Rank on the stock, which
translates into a short-term 'Hold' rating. We are also
maintaining our long-term 'Neutral' recommendation.
However, one of its peers
Feihe International, Inc.
) currently has a Zacks #1 Rank, implying a 'Strong Buy' rating
over the short term.
FEIHE INTL INC (ADY): Free Stock Analysis
LIFEWAY FOODS (LWAY): Free Stock Analysis
To read this article on Zacks.com click here.